Literature DB >> 31955034

Preoperative PET-CT is useful for predicting recurrent extrahepatic metastasis of hepatocellular carcinoma after resection.

Kei Morio1, Tomokazu Kawaoka2, Hiroshi Aikata1, Maiko Namba1, Shinsuke Uchikawa1, Kenichiro Kodama1, Kazuki Ohya1, Hatsue Fujino1, Takashi Nakahara1, Eisuke Murakami1, Masami Yamauchi1, Masataka Tsuge1, Akira Hiramatsu1, Michio Imamura1, Yuko Nakamura3, Motonori Akagi3, Kazuo Awai3, Tsuyoshi Kobayashi4, Hideki Ohdan4, Kazuaki Chayama1.   

Abstract

PURPOSE: In recent years, it has been reported that use of 18F-FDG PET-CT can reveal the degree of hepatocellular carcinoma malignancy. We evaluate the ability of a preoperative 18F-FDG PET-CT to predict the recurrence of extrahepatic metastasis of HCC after surgery.
METHODS: We retrospectively examined 67 patients who received 18F-FDG PET-CT prior to curative hepatic resection for HCC between April 2010 and March 2016. Multivariate Cox regression analysis was performed to identify the factors associated with recurrence of extrahepatic metastasis of HCC after surgery. We also evaluated the sensitivity, specifity, positive predictive value, negative predictive value and accuracy of diagnosis of 18F-FDG PET-CT for recurrent extrahepatic metastasis of HCC after surgery.
RESULTS: The multivariate analysis identified a tumor-to-normal liver standardized uptake value ratio (TNR) ≥ 1.53 (hazard ratio [HR], 0.037; P = 0.003), multiple tumor nodules (HR, 0.121; P = 0.007), and presence of microvascular invasion (HR, 0.094; P = 0.003) as independent predictors of distant metastasis recurrence. A TNR ≥ 1.53 showed a sensitivity of 91.7 %, specificity of 76.4 %, positive predictive value of 45.8 %, negative predictive value of 97.7 %, and accuracy of 79.1 % for diagnosing distant metastasis recurrence of HCC. In a binomial logistic regression analysis of tumor factors associated with a TNR ≥ 1.53, poor tumor differentiation and large tumor size were significant factors.
CONCLUSION: 18F-FDG PET-CT and microvascular invasion may be useful for predicting the recurrence of extrahepatic metastasis of HCC after surgery.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Hepatocellular cancer; Metastasis; PET-CT; Recurrence

Year:  2020        PMID: 31955034     DOI: 10.1016/j.ejrad.2020.108828

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  2 in total

1.  Atezolizumab plus Bevacizumab Followed by Curative Conversion (ABC Conversion) in Patients with Unresectable, TACE-Unsuitable Intermediate-Stage Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2022-07-27       Impact factor: 12.430

Review 2.  HCC: role of pre- and post-treatment tumor biology in driving adverse outcomes and rare responses to therapy.

Authors:  Sandeep Arora; Roberta Catania; Amir Borhani; Natally Horvat; Kathryn Fowler; Carla Harmath
Journal:  Abdom Radiol (NY)       Date:  2021-06-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.